Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Comparing Medications for Adults With Type 2 Diabetes

Slide: 28 of 35

Other Adverse Events and Side Effects: Comparisons of Monotherapies

Liver Injury
High-grade evidence showed that rates of liver injury are similar between thiazolidinediones and sulfonylureas. Moderate-grade evidence showed that the rates of liver injury are similar between thiazolidinediones and metformin.

Hip and Nonhip Fractures
High-grade evidence showed that thiazolidinediones, either in combination with another medication or as monotherapy, are associated with a higher risk of bone fractures compared with metformin alone or in combination with sulfonylurea.

Congestive Heart Failure
Moderate evidence showed that thiazolidinediones increase the risk of heart failure when compared to sulfonylureas. There were no long-term trials that provide a robust assessment of the comparative safety of the DPP-4 inhibitors and GLP-1 receptor agonists on the risk of heart failure.

Severe Lactic Acidosis
Moderate strength of evidence indicated that there is no increased risk of lactic acidosis in metformin users compared to those using a sulfonylurea or a combination of metformin and a sulfonylurea.